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Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is
unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation
analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic
variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample
of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and
prostate cancer case status, stage and grade were assessed by logistic regression and with all-cause and prostate cancer-
specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining
rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI:
0.98,1.03) or having high-grade compared to low-grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that
the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03,
95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and
all-cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These
results, which should have less bias from confounding than observational estimates, are not consistent with a substantial
effect of coffee consumption on reducing prostate cancer incidence or progression.
What’s new?
Does coffee consumption reduce prostate cancer risk? It’s biologically plausible that it could, but studies showing a link have
relied on observational evidence, which could be affected by confounding factors. These authors set out to isolate coffee’s
contribution. They focused on two genetic variants that correspond with caffeine intake, and used them as proxies for coffee
drinking. Alleles are not affected by behavior or demographic factors, nor can behavior changes after diagnosis change
whether a person carries an allele. The authors found no correlation between either of the alleles and prostate cancer risk,
suggesting drinking coffee may not protect against prostate cancer.
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Coffee consumption has been reported to be inversely associ-
ated with prostate cancer risk,1,2 and progression to advanced
disease and mortality.2–6 In a recent meta-analysis of 12 case
control and 9 cohort studies, the odds of prostate cancer
amongst individuals in the highest category of coffee con-
sumption were 0.91 times that in the lowest category.2 Evi-
dence is, however, mixed; not all studies have found strong
evidence for a link between coffee and prostate cancer.7,8 A
protective effect is biologically plausible, given coffee’s abun-
dance of compounds with anti-oxidant and anti-inﬂammatory
effects8 and reported effects on insulin levels.9 However, infer-
ring causality from observational data is difﬁcult due to often
intractable problems of confounding and reverse causality. For
example, coffee consumption is associated with socioeconomic
status, alcohol consumption and smoking.10
Mendelian randomization, which uses genetic variants
that are associated with exposures of interest as proxies for
measured exposures, may help to strengthen causal inference
about potentially modiﬁable exposures.11 Due to the way that
alleles are randomly assigned during gamete formation and
conception, alleles that are associated with coffee consump-
tion should not be associated with lifestyle and demographic
factors which distort the observational relationship between
coffee and prostate cancer.11 Furthermore, as it is not possi-
ble to change the germline genotype that an individual is
born with, reverse causality is not an issue in such analyses.
Genetic variants which demonstrate robust associations
with caffeine intake have been identiﬁed in recent genome-
wide association studies (GWAS) of coffee consumption.12–14
Two key genetic loci are close to the cytochrome P450 1A1/2
(CYP1A1/CYP1A2) and aryl hydrocarbon receptor (AHR)
genes, which are known to play a functional role in caffeine
metabolism.12,14 CYP1A2 is the primary enzyme responsible
for metabolizing caffeine, whilst AHR controls transcription
of CYP1A2.15 Combining variants in these regions into a
multiple allelic genetic risk score increases the proportion of
variance in caffeine consumption explained and hence
increases power.10 It is important to note that these variants
are likely to affect consumption through their effects on caf-
feine metabolism (i.e., slow metabolism of caffeine results in
reduced consumption), so these instruments may have
opposing effects on blood caffeine levels; the allele in AHR
which increases coffee consumption was associated with low-
er blood caffeine in a GWAS of blood metabolites.16
Although these variants appear related to caffeine intake in
general rather than coffee consumption speciﬁcally, they
demonstrate robust associations with coffee consumption.12
Given that many of the proposed mechanisms for the protec-
tive effect of coffee are related to noncaffeine compounds,2
these genetic markers are likely to be informative instruments
for these analyses.
Using variants in these two loci as instruments for coffee
consumption, we performed a Mendelian randomization
analysis in 46,687 prostate cancer cases and controls from
the PRACTICAL consortium to investigate whether coffee
consumption is causally associated with prostate cancer risk,
stage, grade and mortality. If coffee consumption causes a
reduction in prostate cancer risk or progression via com-
pounds other than caffeine, we might expect to see an inverse
relationship between number of coffee consumption increas-
ing alleles and these outcomes.
Materials and Methods
Studies
We used data on prostate cancer cases and controls from 25
studies in the PRACTICAL Consortium (PRostate cancer
AssoCiation group To Investigate Cancer Associated aLtera-
tions in the genome, practical.ccge.medschl.cam.ac.uk). Men
included in the analysis were of European genotypic ancestry.
Full details of the individual participating studies have been
published previously17,18 and are available at: http://www.
nature.com/ng/journal/v45/n4/extref/ng.2560-S1.pdf. All stud-
ies met the appropriate ethical criteria for each country in
accordance with the Declaration of Helsinki.
Genotyping
The two caffeine-related single nucleotide polymorphisms
(SNPs) (rs4410790 in AHR and rs2472297 near CYP1A1/
CYP1A2) were imputed using a HapMap 2 CEU reference
panel from a Custom Inﬁnium genotyping array (iCOGS).
This array was designed for the Collaborative Oncological
Gene-environment Study (COGS) and consisted of 211,155
SNPs (details at: http://ec.europa.eu/research/health/medical-
research/cancer/fp7projects/cogs_en.html).
Full details of the genotyping and imputation have been
published previously.17,18 After quality control, excluding SNPs
with low call rates (<95%) or SNPs that deviated from Hardy
Weinberg Equilibrium in controls (P< 1 3 1027), 201,598
SNPs remained. These SNPs were used to impute 2.6 million
SNPs; poorly imputed SNPs (R2< 0.3) were excluded.19
Genetic risk scores for coffee consumption
Genetic risk scores were created by summing the number of
coffee consumption increasing alleles (the minor allele for
rs2472297 and major allele for rs4410790) for the two SNPs,
assuming an additive genetic model. We used allele dosages
from imputation (which range on a continuous scale from 0
to 2 for each genetic locus) to indicate the number of coffee
increasing alleles. This accounts for uncertainty in the impu-
tation of each genotype.
Cancer stage and grade
Cancers were categorised into low or high grade, according
to Gleason score (low grade 6, high grade 7). Cancers
were categorised into clinically localised and nonlocalised,
using TNM staging (T1/T2/N0/NX/M0/MX for localised, T3/
T4/N1/M1 for nonlocalised) or SEER staging, where TNM
staging was not available (“local” for localised, “regional” or
“distant” for nonlocalised).
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All cause and prostate cancer specific mortality
Analyses were limited to studies for which mortality follow-
up amongst cases was at least 90% complete and had at least
ﬁve prostate cancer deaths (for the prostate cancer-speciﬁc
mortality analysis). Individuals with vital status recorded as
“unknown” were excluded from these analyses. Individuals
with an unknown cause of death were assumed not to have
died of prostate cancer.
Coffee and tea consumption
Data on coffee and tea consumption were available for four of
the studies (ESTHER, FHCRC, MCCS and UKGPCS). Out of
these studies, information on whether coffee or tea was caffein-
ated or decaffeinated was only available in UKGPCS. Informa-
tion about frequency of coffee and tea consumption was
collected in categories, but for the purposes of analysis was
recoded to number of consumed cups per day using the mid-
point of each category. Further details of the coding of these
variables and how coffee and tea data were collected in each
study are available in Supporting Information (Table S1).
Statistical analysis
Analyses were conducted in Stata (version 14). Associations
between the genetic risk score and consumption of coffee, tea
and coffee and tea combined were assessed using linear
regression, adjusting for the top eight principal components
that reﬂect the genetic structure of the population (to control
for confounding by population stratiﬁcation). Robust stan-
dard errors were calculated to account for the right skewed
nature of the coffee and tea variables. Analyses were con-
ducted within each of the four studies with coffee and tea
consumption data available and combined in a random
effects meta-analysis using the metan command in Stata.
Associations between the coffee-related SNPs and prostate
cancer risk (case/control status) were assessed using logistic
regression. For these analyses, we only included studies con-
tributing both cases and controls (N5 23, ProMPT and
WUGS excluded). Within prostate cancer cases, we used
logistic regression to investigate associations of these SNPs
with high grade compared to low grade and nonlocalised
compared to localised cancer. For the nonlocalised vs
Figure 1. Associations of genetic risk score with tea and coffee consumption in ESTHER, FHCRC, MCCS and UKGPCS. [Color figure can be
viewed at wileyonlinelibrary.com]
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localised analysis, we excluded studies with no nonlocalised
cancers (N5 2). In men diagnosed with prostate cancer, we
used Cox proportional hazards regression to investigate wheth-
er the caffeine-related SNPs were associated with all-cause
mortality and prostate cancer-speciﬁc mortality. For these
analyses, we used age at diagnosis as the start date and age of
death or age of last follow up (for individuals who were still
alive at the end of the study) as the censoring date. All analyses
of the associations between the coffee-related genetic variants
and prostate cancer were adjusted for genetic principal compo-
nents and study and robust standard errors were used to
account for clustering by study. To investigate between-study
heterogeneity we calculated estimates separately for each study
and combined these in a ﬁxed effects meta-analysis using the
metan command in Stata. Between-study heterogeneity was
low (I2 34%), so we report the combined estimates.
Results
A total of 46,687 men of European ancestry from 25 studies
in the PRACTICAL consortium contributed to the analyses
(see Supporting Information Table S2). Mean age at prostate
cancer diagnosis was 65 years (SD 8) with mean age across
the studies ranging from 59 to 72 years. Reﬂecting the variety
of clinical populations across the included studies, the
proportion of men with nonlocalised cancer ranged from 0%
to 65% and with high grade cancer from 28% to 84%.
Association of coffee SNPs with coffee and tea
consumption
Data on coffee and/or tea consumption were available for
4,722 individuals (2,591 controls and 2,131 cases). Associa-
tions between the genetic risk score and tea and coffee con-
sumption were in the expected directions and of similar
magnitude to those observed in coffee consumption
GWAS12,13 (Fig. 1). In the combined estimate, each additional
coffee consuming allele was associated with a 0.10 cup (95%
CI: 0.02, 0.19) increase in combined coffee and tea consump-
tion. Associations with coffee (0.06, 95% CI: 20.03, 0.15) and
tea (0.06, 95% CI: 0.003, 0.11) individually were consistent but
weaker. There was evidence for heterogeneity in these estimates
between studies (I2> 33%).
Association of coffee SNPs with prostate cancer risk, stage
and grade
There was no clear evidence that the coffee-related SNPs
were associated with prostate cancer case status or having
high grade compared to low grade disease (Table 1). The
odds ratios (OR) for prostate cancer and high grade disease
Table 1. Associations of coffee related SNPs with prostate cancer risk, stage and grade
N OR1 95% CI p values I-squared (%)
rs4410790
Controls 23,034 – – –
All prostate cancers 22,721 1.00 0.99 1.02 0.64 0
Localised 14,908 – – –
Nonlocalised 4,850 1.03 0.99 1.08 0.12 0
Low grade 9,622 – – –
High grade 9,293 1.00 0.95 1.06 0.92 21
rs2472297
Controls 23,034 – – –
All prostate cancers 22,721 1.01 0.97 1.05 0.67 19
Localised 14,908 – – –
Nonlocalised 4,850 1.03 0.99 1.08 0.13 0
Low grade 9,622 – – –
High grade 9,293 1.01 0.96 1.07 0.63 12
Genetic risk score
Controls 23,034 – – –
All prostate cancers 22,721 1.01 0.98 1.03 0.58 2
Localised 14,908 – – –
Nonlocalised 4,850 1.03 1.01 1.06 0.02 0
Low grade 9,622 – – –
High grade 9,293 1.01 0.97 1.04 0.68 12
Analyses are adjusted for principal components and study and robust standard errors used to account for within study clustering. For the case con-
trol analyses, the following studies did not contribute data: ProMPT, WUGS. For analyses of prostate cancer stage, the following studies did not con-
tribute data: CPCS1, CPCS2, EPIC- Norfolk, QLD. For analyses of prostate cancer grade, the following studies did not contribute data: MEC, UTAH.
1Associations are per coffee consumption increasing allele.
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per additional coffee increasing allele in the genetic risk score
were 1.01 (95% CI: 0.98 to 1.03) and 1.01 (95% CI: 0.97 to
1.04) respectively. However, there was suggestive evidence
that the genetic risk score for coffee consumption was associ-
ated with higher odds of nonlocalised disease (OR per coffee
increasing allele 1.03, 95% CI: 1.01 to 1.06).
Association of coffee SNPs with all-cause and prostate
cancer-specific mortality
The 15,555 men who contributed to the all-cause mortality
analysis were followed up for an average of 6.8 years, during
which 4,081 died. The 14,010 men who contributed to the
prostate-cancer speciﬁc analysis were followed up for an
average of 7.1 years during which 1,754 died of prostate can-
cer. There was no clear evidence that the individual coffee
related SNPs or the genetic risk score for coffee consumption
were associated with all-cause mortality (hazard ratio per cof-
fee increasing allele of the genetic risk score: 1.00 (95% CI:
0.97 to 1.04)) or with prostate cancer mortality: HR 1.03
(95% CI: 0.98 to 1.08) (Table 2). There was no evidence to
suggest that the proportional hazards assumption of Cox
regression was not met in this analysis.
Discussion
We performed a Mendelian randomization analysis in a large
prostate cancer case control study to investigate whether cof-
fee consumption causally inﬂuences prostate cancer incidence
and progression. We found no clear evidence to suggest that
coffee consumption is causally associated with risk of prostate
cancer, disease grade or mortality amongst men diagnosed
with prostate cancer.
Our ﬁndings suggest that observational associations indi-
cating that coffee consumption reduce prostate cancer risk
and progression1,3,4,20 may not be causal and could be
explained by residual confounding or by other lifestyle or
demographic factors. Given that the associations between the
genetic risk score and blood caffeine levels may be null or in
the opposing direction to coffee consumption,16 we cannot
use these results to draw strong conclusions about any poten-
tial role of caffeine in the development of prostate cancer.
Our ﬁnding of a weak positive association between the
coffee genetic risk score and increased risk of nonlocalised
disease is in the opposite direction to observational evidence
suggesting that coffee may reduce risk of disease progres-
sion.3 Interestingly, this raises the possibility that higher cof-
fee, tea or caffeine consumption or, conversely, that lower
blood caffeine levels (due to faster caffeine metabolism) could
be associated with progression to more severe disease. How-
ever, given that the case deﬁnition for prostate cancer
(including stage of cancer cases) and quality of survival
follow-up data differed between studies, we cannot rule out
the possibility that this result could be due to selection bias.
This ﬁnding requires replication in further studies before any
conclusions can be made with respect to causality.
There are several limitations to these analyses. First, as
aforementioned, there is heterogeneity between studies in
terms of case deﬁnition, treatment received, classiﬁcation of
stage, grade and mortality follow up. Second, as discussed
previously and shown by the associations in the four PRAC-
TICAL studies with caffeine consumption data, these genetic
instruments are not speciﬁc to coffee and associate with con-
sumption of other caffeinated beverages (e.g., tea), and even
with decaffeinated coffee.10,13 Although we did not ﬁnd
strong evidence for an association with coffee speciﬁcally in
our subsample, coffee consumption is widespread in most
European and North American populations, so it is likely
that coffee is consumed at high enough levels in the full sam-
ple for the genetic instrument to be sufﬁciently strongly asso-
ciated with coffee.21,22 Whilst we cannot attribute any effects
of these variants to coffee speciﬁcally, lack of a negative asso-
ciation of these SNPs with prostate cancer outcomes still pro-
vides evidence against coffee being protective for prostate
Table 2. Associations of coffee related SNPs with all-cause and prostate cancer-specific mortality in prostate cancer cases
N N deaths
Years at
risk (1000s) HR1 95% CI p values I-squared (%)
rs4410790
All-cause 15,555 4,081 106 1.01 0.98 1.03 0.70 0
Prostate cancer-specific 14,010 1,754 100 1.02 0.98 1.07 0.35 7
rs2472297
All-cause 15,555 4,081 106 1.00 0.92 1.08 0.95 0
Prostate cancer-specific 14,010 1,754 100 1.04 0.96 1.13 0.33 29
Genetic risk score
All-cause 15,555 4,081 106 1.00 0.97 1.04 0.91 0
Prostate cancer-specific 14,010 1,754 100 1.03 0.98 1.08 0.22 34
Analyses are adjusted for principal components and study and robust standard errors used to account for within study clustering. For analyses of
all-cause mortality, the following studies contributed data: CAPS, CPCS1, EPIC, ESTHER, FHCRC, IPO-Porto, MAYO, MEC, PPF-UNIS, Poland, SEARCH,
TAMPERE, UKGPCS, UTAH, WUGS. For analyses of prostate cancer mortality, the following studies contributed data: CAPS, CPCS1, EPIC, ESTHER,
FHCRC, MAYO, MEC, PPF-UNIS, SEARCH, TAMPERE, UKGPCS, UTAH.
1Associations are per coffee consumption increasing allele.
C
an
ce
r
E
pi
de
m
io
lo
gy
6 Coffee and prostate cancer
Int. J. Cancer: 00, 00–00 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
cancer. Thirdly, we were also unable to test the association of
these instruments with potential confounders of the coffee-
prostate cancer relationship within these samples so cannot
rule out the possibility of pleiotropy (that the genetic variants
act on prostate cancer through pathways unrelated to coffee/
caffeine consumption). SNPs in these gene regions (AHR and
CYP1A1/2) have been identiﬁed in GWAS of blood pressure,
bladder cancer and Parkinson’s disease,23,24 although these
may be explained by downstream effects of caffeine or coffee
consumption or metabolism. We know that CYP1A2 metabo-
lises other xenobiotic substrates other than caffeine and
although neither of the SNPs used in this analysis were found
to associate with blood metabolites (other than caffeine) at
genome wide signiﬁcance level,16 we cannot rule out the pos-
sibility that associations with prostate cancer occur via
metabolism of these other compounds. In addition, cigarette
smoking increases caffeine metabolism via induction of
CYP1A2,25 so it is possible that effects could differ in smok-
ers and nonsmokers. In the subsample with information on
smoking data, we found no clear evidence that the associa-
tion of the genetic risk score with prostate cancer differed
between ever and never smokers (Supporting Information
Fig. 1). However, it is unlikely that we had sufﬁcient power
to detect an interaction. Finally, statistical power to detect
associations in Mendelian randomization studies is substan-
tially lower than conventional observational analyses.
Although point estimates are very close to the null for most
ﬁndings, we cannot rule out the possibility that coffee may
have small effects on prostate cancer. For example, the meta-
analysis of coffee and prostate cancer conducted by Lu and
colleagues in 2014 reports an OR of 0.96 for prostate cancer
risk for the highest (at least 4 cups per day) compared to
the lowest categories of consumption (generally< 1 cup per
day).2 This would equate to an OR close to 0.999 for prostate
cancer risk per additional 0.06 cups of coffee consumed. Our
analysis was only powered to detect ORs in the region of
0.98 per additional 0.06 cups of coffee consumed.
In conclusion, our ﬁndings do not support a causal role of
coffee consumption in prostate cancer incidence or grade and
suggest that observational ﬁndings that coffee consumption is
associated with a reduced risk for prostate cancer may be due
to confounding by other lifestyle factors. Further investiga-
tion of our ﬁnding that the genetic risk score was positively
associated with risk of nonlocalised disease is required in
samples which also have data on coffee consumption, and
which have greater power to investigate a subsequent impact
on prostate cancer speciﬁc mortality.
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